NextBioMedical Co Ltd
KOSDAQ:389650
NextBioMedical Co Ltd
Research & Development
NextBioMedical Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NextBioMedical Co Ltd
KOSDAQ:389650
|
Research & Development
-₩6.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
I Sens Inc
KOSDAQ:099190
|
Research & Development
-₩28.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-12%
|
|
|
C
|
Classys Inc
KOSDAQ:214150
|
Research & Development
-₩16.7B
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
W
|
Won Tech Co Ltd
KOSDAQ:336570
|
Research & Development
-₩1.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Viol Co Ltd
KOSDAQ:335890
|
Research & Development
-₩2.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Seers Technology Co Ltd
KOSDAQ:458870
|
Research & Development
-₩4.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
NextBioMedical Co Ltd
Glance View
NextBioMedical Co Ltd is a KR-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Incheon, Incheon. The company went IPO on 2024-08-20. NextBioMedical Co Ltd is a Korea-based company mainly engaged in the manufacturing and sales of medical equipment. The firm is mainly engaged in the manufacturing and sales of medical equipment, such as endoscopic hemostatic agents and vascular embolic microspheres. In addition, the Company is also engaged in the research and development of medical equipment.
See Also
What is NextBioMedical Co Ltd's Research & Development?
Research & Development
-6.6B
KRW
Based on the financial report for Dec 31, 2024, NextBioMedical Co Ltd's Research & Development amounts to -6.6B KRW.
What is NextBioMedical Co Ltd's Research & Development growth rate?
Research & Development CAGR 1Y
-38%
Over the last year, the Research & Development growth was -38%.
